Zacks Research Upgrades vTv Therapeutics (NASDAQ:VTVT) to “Hold”

vTv Therapeutics (NASDAQ:VTVT) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Monday, Zacks reports.

Several other research analysts have also weighed in on VTVT. Wall Street Zen lowered shares of vTv Therapeutics from a “buy” rating to a “sell” rating in a report on Saturday, August 8th. Rodman & Renshaw began coverage on vTv Therapeutics in a report on Tuesday, June 30th. They issued a “buy” rating and a $67.00 price objective for the company. BTIG Research lifted their target price on vTv Therapeutics from $49.00 to $57.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. Weiss Ratings lowered vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, Lifesci Capital upgraded shares of vTv Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $55.83.

vTv Therapeutics Stock Performance

Shares of NASDAQ VTVT opened at $32.79 on Monday. vTv Therapeutics has a 1 year low of $18.77 and a 1 year high of $44.00. The firm has a market cap of $129.19 million, a price-to-earnings ratio of -30.93 and a beta of 0.29. The stock’s 50-day simple moving average is $32.86 and its 200-day simple moving average is $34.51.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.08). As a group, research analysts predict that vTv Therapeutics will post -2.35 EPS for the current year.

Hedge Funds Weigh In On vTv Therapeutics

Several institutional investors have recently modified their holdings of VTVT. Geode Capital Management LLC increased its holdings in shares of vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after acquiring an additional 12,896 shares during the period. Goldman Sachs Group Inc. acquired a new position in vTv Therapeutics during the 4th quarter valued at about $221,000. Finally, 683 Capital Management LLC acquired a new position in vTv Therapeutics during the 4th quarter valued at about $731,000. Institutional investors own 17.51% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.